Tagrisso and Sleep disorder - a phase IV clinical study of FDA data

Summary:

Sleep disorder is reported as a side effect among people who take Tagrisso (osimertinib mesylate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Iressa, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Sleep disorder when taking Tagrisso. It is created by eHealthMe based on reports of 19,861 people who have side effects when taking Tagrisso from the FDA, and is updated regularly.

What is Tagrisso?

Tagrisso has active ingredients of osimertinib mesylate. eHealthMe is studying from 19,891 Tagrisso users. Check the latest studies of Tagrisso.

What is Sleep disorder?

Sleep disorder is found to be associated with 2,099 drugs and 2,943 conditions by eHealthMe. Check the latest studies of Sleep disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

19,861 people reported to have side effects when taking Tagrisso.
Among them, 22 people (0.11%) have Sleep disorder.

Among these 22 people:

How long have people been on Tagrisso when they have Sleep disorder? *

What is the gender of people who have Sleep disorder when taking Tagrisso? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Sleep disorder when taking Tagrisso? *

What are other drugs people take besides Tagrisso? *

What are other side effects people have besides Sleep disorder? *

Diarrhea: 7 people, 31.82%
Rashes (redness): 6 people, 27.27%
Malignant Neoplasm Progression (cancer tumour came back): 5 people, 22.73%
Fatigue (feeling of tiredness): 5 people, 22.73%
Itching: 3 people, 13.64%
Electrocardiogram Qt Prolonged: 3 people, 13.64%
Drug Resistance (reduction in effectiveness of a drug): 3 people, 13.64%
Pain In Extremity: 3 people, 13.64%
Oropharyngeal Pain: 3 people, 13.64%
Urinary Tract Infection: 3 people, 13.64%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 6 people, 27.27%
Lung Neoplasm Malignant (cancer tumour of lung): 5 people, 22.73%
Neoplasm Malignant (cancer tumour): 3 people, 13.64%
Gastric Ulcer (stomach ulcer): 2 people, 9.09%
Non-Small Cell Lung Cancer Stage Iv: 2 people, 9.09%
Metastases To Central Nervous System (cancer spreads to central nervous system): 2 people, 9.09%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 1 person, 4.55%
Constipation: 1 person, 4.55%
Insomnia (sleeplessness): 1 person, 4.55%
Itching: 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Tagrisso and have Sleep disorder?

- Check whether Sleep disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tagrisso:

Tagrisso (19,891 reports)

Sleep disorder treatments and more:

Sleep disorder (167,338 reports)

Browse all side effects of Tagrisso:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sleep disorder:

Sleep disorder (2,099 drugs)

Browse all the conditions that are associated with Sleep disorder:

Sleep disorder (2,943 conditions)

Related publications that referenced our studies

Lin SC, Su YC, Huang YS, Lee CC, "Zolpidem increased cancer risk in patients with sleep disorder: A 3-year follow-up study", Journal of Medical Sciences, 2016 Mar .
Lin SC, Su YC, Huang YS, Lee CC, "Zolpidem increased cancer risk in patients with sleep disorder: A 3-year follow-up study", Journal of Medical Sciences, 2016 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on osimertinib mesylate (the active ingredients of Tagrisso) and Tagrisso (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.